These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 30524432)

  • 1. Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients.
    Kaufmann M; Haase R; Proschmann U; Ziemssen T; Akgün K
    Front Immunol; 2018; 9():2669. PubMed ID: 30524432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod.
    Ghadiri M; Fitz-Gerald L; Rezk A; Li R; Nyirenda M; Haegert D; Giacomini PS; Bar-Or A; Antel J
    Mult Scler; 2017 Aug; 23(9):1225-1232. PubMed ID: 28749311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
    Boffa G; Bruschi N; Cellerino M; Lapucci C; Novi G; Sbragia E; Capello E; Uccelli A; Inglese M
    CNS Drugs; 2020 Apr; 34(4):425-432. PubMed ID: 32193826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fingolimod Profoundly Reduces Frequencies and Alters Subset Composition of Circulating T Follicular Helper Cells in Multiple Sclerosis Patients.
    Huber JE; Chang Y; Meinl I; Kümpfel T; Meinl E; Baumjohann D
    J Immunol; 2020 Mar; 204(5):1101-1110. PubMed ID: 32034063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.
    Song ZY; Yamasaki R; Kawano Y; Sato S; Masaki K; Yoshimura S; Matsuse D; Murai H; Matsushita T; Kira J
    PLoS One; 2014; 10(4):e0124923. PubMed ID: 25919001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Resolution Expression Profiling of Peripheral Blood CD8
    Roch L; Hecker M; Friess J; Angerer IC; Koczan D; Fitzner B; Schröder I; Flechtner K; Thiesen HJ; Meister S; Winkelmann A; Zettl UK
    Mol Neurobiol; 2017 Sep; 54(7):5511-5525. PubMed ID: 27631876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocyte recovery after fingolimod discontinuation in patients with MS.
    Nagy S; Kuhle J; Derfuss T
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32801166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.
    Delgado S; Hernandez J; Tornes L; Rammohan K
    BMC Neurol; 2021 Feb; 21(1):48. PubMed ID: 33530945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of CD4+ and CD8+ T Cell Subsets and Interferon Regulatory Factor 4 (IRF4) in MS Patients Treated with Fingolimod (FTY-720): A Follow-up Study.
    Laribi B; Sahraian MA; Shekarabi M; Emamnejad R; Marzban M; Sadaghiani S; Izad M
    Iran J Allergy Asthma Immunol; 2018 Aug; 17(4):346-360. PubMed ID: 30537798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets.
    Hjorth M; Dandu N; Mellergård J
    PLoS One; 2020; 15(2):e0228380. PubMed ID: 32012202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients.
    Kürtüncü M; Yılmaz V; Akçay Hİ; Türkoğlu R; Altunrende B; Çınar SA; Ulusoy C; Gündüz T; İçöz S; Kasap M; Çalışkan Z; Ötünç G; Eraksoy M; Tüzün E
    J Neuroimmunol; 2019 Dec; 337():577065. PubMed ID: 31526917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
    Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
    Kemmerer CL; Pernpeintner V; Ruschil C; Abdelhak A; Scholl M; Ziemann U; Krumbholz M; Hemmer B; Kowarik MC
    PLoS One; 2020; 15(7):e0235449. PubMed ID: 32716916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis.
    Henault D; Galleguillos L; Moore C; Johnson T; Bar-Or A; Antel J
    Neurology; 2013 Nov; 81(20):1768-72. PubMed ID: 24132373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.
    Fleischer V; Friedrich M; Rezk A; Bühler U; Witsch E; Uphaus T; Bittner S; Groppa S; Tackenberg B; Bar-Or A; Zipp F; Luessi F
    Mult Scler; 2018 Apr; 24(5):632-641. PubMed ID: 28436295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphopenia in Multiple Sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells.
    Abbadessa G; Maida E; Miele G; Lavorgna L; Marfia GA; Valentino P; De Martino A; Cavalla P; Bonavita S
    Mult Scler Relat Disord; 2022 Apr; 60():103740. PubMed ID: 35305426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation.
    Thomas K; Sehr T; Proschmann U; Rodriguez-Leal FA; Haase R; Ziemssen T
    J Neuroinflammation; 2017 Feb; 14(1):41. PubMed ID: 28231856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment.
    Hawke S; Zinger A; Juillard PG; Holdaway K; Byrne SN; Grau GE
    J Neuroimmunol; 2020 Dec; 349():577392. PubMed ID: 33007647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.
    Fragoso YD; Spelman T; Boz C; Alroughani R; Lugaresi A; Vucic S; Butzkueven H; Terzi M; Havrdova E; Horakova D; Granella F; Olascoaga J; Sánchez-Menoyo JL; Pucci E; Barnett M; Brooks JBB; Haartsen J;
    Mult Scler Relat Disord; 2018 Jan; 19():105-108. PubMed ID: 29182993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients.
    Chiarini M; Sottini A; Bertoli D; Serana F; Caimi L; Rasia S; Capra R; Imberti L
    Mult Scler; 2015 May; 21(6):726-34. PubMed ID: 25392322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.